Hong Kong stock ETFs get record China money on AI, biotech craze
Mainland retail traders are being lured by the outperformance of the city’s equities, combined with their accessibility and abundance of ...
Tag: Biotech
Biotech company Amgen set to build $600-million research center in Thousand Oaks
Biotech company Amgen is investing $600 million into a new research center for its Thousand Oaks campus. The new site ...
A*Star biotech spin-off Mirxes trims losses to US$28.4 million as top line grows
Higher revenue is driven by increased contributions from its early detection and precision multi-omics segment Local biotech startup Mirxes on ...
Australian biotech giant CSL to spin off vaccine unit Seqirus, cut 15% of workforce
While the Melbourne-based company employs around 32,000 people, no firm number was put on the job cuts Published Tue, Aug ...
China’s biotech moment ignites a 60% stock rally that beats AI
China’s biotechnology stocks have shaken off a four-year slump to be among the hottest performers in Asia this year and ...
Sanofi to buy immunology biotech Blueprint for US$9.1 billion
Sanofi agreed to buy Blueprint Medicines for at least US$9.1 billion as the French drugmaker expands further in rare immunological ...
Singapore-based biotech firm Nuevocor raises US$45 million in Series B round
Biotechnology company Nuevocor announced on Wednesday (May 7) that it completed a US$45 million Series B funding round from new ...
Initial MAS review group incentives could pull in regional biotech, fintech players: observers
High-growth companies in the technology, healthcare and sustainability-linked industries are potential entrants, tooMARKET watchers believe tax incentives proposed by the ...
MAS review group incentives could pull in regional biotech, fintech players: observers
High-growth companies in the technology, healthcare and sustainability-linked industries are potential entrants, tooMARKET watchers believe tax incentives proposed by the ...
GSK to buy US cancer biotech IDRx for up to US$1.15 billion
GSK agreed to buy US biotech IDRx for as much as US$1.15 billion to gain new cancer medicines. The UK drugmaker ...
The NY Journals pride themselves on assembling a proficient and dedicated team comprising seasoned journalists and editors. This collective commitment drives us to provide our esteemed readership with nothing short of the most comprehensive, accurate, and captivating news coverage available.
Transcending the bounds of New York City to encompass a broader scope, we ensure that our audience remains well-informed and engaged with the latest developments, both locally and beyond.
NEWS
- Business
- Technology
- Entertainment
- Sports
- Lifestyle
- Health
- Politics
- Real Estate
© 2025 The New York Journals. All Rights Reserved.